Jonathan D. Lippiat

This study identifies eight structurally diverse KCNT1 channel inhibitors through virtual screening and experimental validation, offering potential new treatments for KCNT1-associated epilepsy.

This study identifies KCNJ2, KCNJ13, and KCNMA1 as potassium channels facilitating Bunyamwera virus escape from late endosomes.

This study identifies two existing drugs that reduce KCNT1 channel activity and seizure activity in Drosophila models, suggesting potential new treatments for KCNT1-epilepsy.

This paper identifies a molecular switch in the RCK2 domain of KNa1.1 channels that mediates sodium-dependent activation through conformational changes involving specific amino acid residues.

This study models human KCNT1-epilepsy in Drosophila by expressing patient mutations and shows drug responses, demonstrating the utility of Drosophila as a model for assessing treatments.

This study investigates how epilepsy-causing KCNT1 variants increase KNa1.1 channel activity by disrupting activation and selectivity filter gates.